SLNO Vykat is dosed by weight. Based on the average weight of patients in its clinical trials, the drug will cost $466,200 per year
Vykat's approval unlocks a market opportunity that analysts at investment firm Stifel estimate is worth more than $1.5 billion annually
Cantor/ $SLNO: This Vy"kat" XR Will Roar; A Best-Case Scenario for the PWS Community- raising price target to $123 (that's about $5B)
Considering that Soleno only has this one drug approved, how much is Neuren worth now? And how much will it be worth with PMD approved, which has nearly double the patients of PW?
https://www.biopharmadive.com/news/soleno-fda-approval-prader-willi/743563/
SLNO Vykat is dosed by weight. Based on the average weight of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.26 |
Change
-0.280(2.23%) |
Mkt cap ! $1.525B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $6.952M | 570.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 231 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.32 | 1979 | 2 |
View Market Depth
| Last trade - 16.13pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |